Dianthus Therapeutics, Inc. (DNTH) Return on equity 2018–2025
Dianthus Therapeutics, Inc. (DNTH) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-32.9%FY2025 · since FY2018: -39.5% → -32.9%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -32.9% | -8.8 pp |
| FY2024 | -24.1% | +1.7 pp |
| FY2023 | -25.8% | — |
| FY2019 | -54.4% | -14.9 pp |
| FY2018 | -39.5% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice